Cargando…

Exosome markers of LRRK2 kinase inhibition

Hyper-activated LRRK2 is linked to Parkinson’s disease susceptibility and progression. Quantitative measures of LRRK2 inhibition, especially in the brain, maybe critical in the development of successful LRRK2-targeting therapeutics. In this study, two different brain-penetrant and selective LRRK2 sm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shijie, Kelly, Kaela, Brotchie, Jonathan M., Koprich, James B., West, Andrew B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666125/ https://www.ncbi.nlm.nih.gov/pubmed/33298972 http://dx.doi.org/10.1038/s41531-020-00138-7

Ejemplares similares

Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics
por: Kelly, Kaela, et al.
Publicado: (2020)

Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers
por: Wang, Shijie, et al.
Publicado: (2017)

Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein
por: Brzozowski, Charlotte F., et al.
Publicado: (2021)

Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity
por: Nguyen, An Phu Tran, et al.
Publicado: (2020)

Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity
por: Fernández, Belén, et al.
Publicado: (2022)

Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization
por: De Wit, T., et al.
Publicado: (2018)

Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
por: Lobbestael, E., et al.
Publicado: (2016)

Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque
por: Koprich, James B., et al.
Publicado: (2016)

Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease
por: Grotemeyer, Alexander, et al.
Publicado: (2023)

Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease
por: Lee, Byoung Dae, et al.
Publicado: (2010)

Inhibition of LRRK2 kinase activity stimulates macroautophagy()
por: Manzoni, Claudia, et al.
Publicado: (2013)

Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease
por: Koprich, James B, et al.
Publicado: (2010)

Dynamic and redundant regulation of LRRK2 and LRRK1 expression
por: Biskup, Saskia, et al.
Publicado: (2007)

GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
por: Schneider, Jay S., et al.
Publicado: (2019)

LRRK2 Kinase Activity Is Dependent on LRRK2 GTP Binding Capacity but Independent of LRRK2 GTP Binding
por: Taymans, Jean-Marc, et al.
Publicado: (2011)

Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition
por: Smith, G. A., et al.
Publicado: (2015)

Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein
por: Koprich, James B., et al.
Publicado: (2011)

Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain
por: Xu, Enquan, et al.
Publicado: (2022)

Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α‐synuclein Parkinson's disease rat model
por: Musacchio, Thomas, et al.
Publicado: (2017)

Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies
por: Davies, Paul, et al.
Publicado: (2013)

Assaying the Kinase Activity of LRRK2 in vitro
por: Lewis, Patrick A.
Publicado: (2012)

Identification and Characterization of a Leucine-Rich Repeat Kinase 2 (LRRK2) Consensus Phosphorylation Motif
por: Pungaliya, Pooja P., et al.
Publicado: (2010)

Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease
por: Gonzalez-Hunt, C. P., et al.
Publicado: (2020)

Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice
por: Korecka, Joanna A., et al.
Publicado: (2020)

The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson’s Disease
por: Titze-de-Almeida, Simoneide S., et al.
Publicado: (2020)

Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?
por: Rudenko, Iakov N, et al.
Publicado: (2012)

Interaction of LRRK2 with kinase and GTPase signaling cascades
por: Boon, Joon Y., et al.
Publicado: (2014)

LRRK2 and ubiquitination: implications for kinase inhibitor therapy
por: Melrose, Heather L.
Publicado: (2015)

Rab GTPases as Physiological Substrates of LRRK2 Kinase
por: Seol, Wongi, et al.
Publicado: (2019)

AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease
por: Ip, Chi Wang, et al.
Publicado: (2017)

LRRK2 is involved in the chemotaxis of neutrophils and differentiated HL-60 cells, and the inhibition of LRRK2 kinase activity increases fMLP-induced chemotactic activity
por: Mazaki, Yuichi, et al.
Publicado: (2023)

Expression Analysis of Lrrk1, Lrrk2 and Lrrk2 Splice Variants in Mice
por: Giesert, Florian, et al.
Publicado: (2013)

LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase
por: Choi, Insup, et al.
Publicado: (2015)

LRRK2 levels in immune cells are increased in Parkinson’s disease
por: Cook, D. A., et al.
Publicado: (2017)

LRRK2: Cause, Risk, and Mechanism
por: Paisán-Ruiz, Coro, et al.
Publicado: (2013)

Ciliogenesis is Not Directly Regulated by LRRK2 Kinase Activity in Neurons
por: Kim, Hyejung, et al.
Publicado: (2021)

Non-steric-zipper models for pathogenic α-synuclein conformers
por: Schuman, Brock, et al.
Publicado: (2018)

Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers
por: Thaler, Avner, et al.
Publicado: (2021)

LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein
por: Marker, Daniel F, et al.
Publicado: (2012)

Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson’s disease and pharmacodynamic biomarkers
por: Taymans, Jean-Marc, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4hldbmsrnmmmj77v8bpeqk7f2f